Results 101 to 110 of about 26,327 (353)
No Aldosterone Breakthrough With the Neprilysin Inhibitor Sacubitril
Journal of the American College of Cardiology, 2019 Cellular and molecular bases of the beneficial effects of sacubitril/valsartan, an angiotensin receptor/neprilysin inhibitor approved for treatment of heart failure with reduced ejection fraction, remain to be elucidated, because of the lack of preclinical mechanistic studies.
Vergaro G., Passino C., Emdin M.
openaire +3 more sources
Circulating neprilysin clears brain amyloid [PDF]
Molecular and Cellular Neuroscience, 2010 The use of the peptidase neprilysin (NEP) as a therapeutic for lowering brain amyloid burden is receiving increasing attention. We have previously demonstrated that peripheral expression of NEP on the surface of hindlimb muscle lowers brain amyloid burden in a transgenic mouse model of Alzheimer's disease.
Christa M. Studzinski +5 more
openaire +3 more sources
Implementation of guideline‐recommended medical therapy for patients with heart failure in Europe
ESC Heart Failure, Volume 12, Issue 2, Page 790-798, April 2025.Abstract Physicians' adherence to guideline‐recommended heart failure (HF) treatment remains suboptimal, especially regarding the target doses. In particular, there is evidence that non‐cardiologists are less compliant with HF guideline recommendations. This is likely to have a detrimental impact on patients' survival, readmissions and quality of life.
Maurizio Volterrani +11 more
wiley +1 more source
Journal of the American College of Cardiology, 2016 Neprilysin is a zinc-dependent endopeptidase. It is ubiquitous in distribution and promiscuous in function, with >50 putative peptide substrates with varying levels of in vitro and/or in vivo evidence of functional relevance. In the first part of this review, we discuss the genetic, structural, substrate, and pathophysiological aspects of neprilysin ...
Antoni Bayes-Genis +2 more
openaire +3 more sources
ESC Heart Failure, Volume 12, Issue 2, Page 1183-1193, April 2025.Abstract Aims The prognostic significance of left ventricular (LV) diastolic dysfunction (LVDD) severity in patients with dilated cardiomyopathy (DCM) remains uncertain. This study aimed to evaluate the association of LVDD severity and elevated left atrial pressure (eLAP) with patient outcomes in stable, non‐acutely decompensated patients with DCM ...
Mateusz Winiarczyk +12 more
wiley +1 more source
BMC Neuroscience, 2008 Background Proteolytic degradation has emerged as a key pathway involved in controlling levels of the Alzheimer's disease (AD)-associated amyloid-β (Aβ) peptide in the brain.
Patrick Christina +9 more
doaj +1 more source
Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma
Endocrine Connections, 2020 Aims: Neprilysin degrades natriuretic peptides in circulation and is also suggested to degrade the gut hormones gastrin and cholecystokinin. Neprilysin inhibition has become a therapeutic strategy and thus a regimen in need of further testing in terms of
Ulrik Ø Andersen +7 more
doaj +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1203-1216, April 2025.The 366 patients diagnosed with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) were analyzed regarding their clinical characteristics in the first year after approval of tafamidis 61 mg for ATTR‐CM in Germany. Nearly two‐thirds of the patients were in an advanced disease stage and 64% met the key criteria of the “Transthyretin Amyloidosis ...
Richard J. Nies +23 more
wiley +1 more source
Neurobiology of Disease, 2006 Converging evidence links abnormally high brain concentrations of amyloid-β peptides (Aβ) to the pathology of Alzheimer's disease (AD). Lowering brain Aβ levels, therefore, is a therapeutic strategy for the treatment of AD.
Raphael Poirier +6 more
doaj +1 more source